NVO
Novo Nordisk A/S
96.65
USD
This page is just a preview of the data found in TrendSpider’s full version
Novo Nordisk A/S stock is down -4.49% since 30 days ago. The next earnings date is Jan 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.09% of the previous 42 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 08 Dec 14:59 | 15 Mar, 2024 | 97.50 | 359 | ||
| 08 Dec 15:00 | 21 Jun, 2024 | 95.00 | 287 | ||
| 08 Dec 15:23 | 17 Jan, 2025 | 95.00 | 186 | ||
| 08 Dec 16:26 | 15 Dec, 2023 | 130.00 | 0 | ||
| 08 Dec 17:25 | 21 Jun, 2024 | 95.00 | 229 | ||
| 08 Dec 17:28 | 21 Jun, 2024 | 125.00 | 95 | ||
| 08 Dec 17:38 | 12 Jan, 2024 | 102.00 | 3 | ||
| 08 Dec 18:57 | 26 Jan, 2024 | 96.00 | 0 | ||
| 08 Dec 20:33 | 17 Jan, 2025 | 95.00 | 186 | ||
| 08 Dec 20:45 | 12 Jan, 2024 | 100.00 | 1 |
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
